Fidelity Investments
INTS icon

Fidelity Investments’s Intensity Therapeutics INTS Stock Holding History

Fidelity Investments’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4
Closed -$31 – 5483
2025
Q2 		$31 Buy
+4
New +$82 ﹤0.01% 5217

Other funds holding INTS

SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
SFGP
Stonebridge Financial Group (Pennsylvania) Wormleysburg, Pennsylvania $1.32B AUM 23.07% 1-Year Est. Return

Fidelity Investments's INTS Position: Q3 2025 in Review

Fidelity Investments sold out of Intensity Therapeutics (INTS) in Q3 2025, closing a stake of 4 shares — an estimated $31 sold.

Fidelity Investments first reported a position in INTS in Q2 2025 and held it in 1 quarter. The position peaked at $31 in Q2 2025. 26 funds tracked by Wall St. Rank hold INTS as of Q3 2025.

  • Fidelity Investments reported no remaining Intensity Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Fidelity Investments sold 4 Intensity Therapeutics shares in Q3 2025, an estimated $31.
  • Fidelity Investments first reported a position in Intensity Therapeutics in Q2 2025 and held it in 1 quarter.
  • Fidelity Investments's Intensity Therapeutics position peaked at $31 in Q2 2025.
  • 26 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q3 2025.

Based on Fidelity Investments's 13F filing for Q3 2025, filed 13 Nov 2025.